Handelsbanken Fonder AB Sells 52,327 Shares of IQVIA Holdings Inc. $IQV

Handelsbanken Fonder AB decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 28.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 131,989 shares of the medical research company’s stock after selling 52,327 shares during the period. Handelsbanken Fonder AB owned 0.08% of IQVIA worth $25,070,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Artisan Partners Limited Partnership bought a new position in IQVIA during the 2nd quarter worth approximately $515,772,000. Norges Bank bought a new position in IQVIA during the second quarter worth $270,160,000. AQR Capital Management LLC lifted its holdings in IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares during the period. Laurel Wealth Advisors LLC grew its holdings in IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after acquiring an additional 774,681 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after acquiring an additional 581,157 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

IQV opened at $179.09 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a market cap of $30.39 billion, a price-to-earnings ratio of 22.79, a PEG ratio of 1.72 and a beta of 1.37. The company’s fifty day moving average price is $212.19 and its two-hundred day moving average price is $208.00. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same period last year, the company earned $3.12 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. UBS Group decreased their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. TD Cowen boosted their target price on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Citigroup dropped their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $231.80.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.